MISSISSAUGA, Ontario, May 19, 2005 (PRIMEZONE) -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article by Glenn Wilkins, an AllPennyStocks.com News Reporter, this one discussing Xenomics Inc. (OTCBB:XNOM), its industry and future prospects.
Wilkins notes that developments in medicine are coming along every day to prolong life and improve it. But such research is often costly, which is why, when a company comes across technologies which promise and deliver major breakthroughs, investors are best advised to pay attention. New York City-based Xenomics Incorporated (OTCBB:XNOM) is one such company, a development stage molecular diagnostic company focusing on the development of DNA-based tests using Transrenal DNA or Tr-DNA.
Wilkins also points out that Tr-DNAs are fragments of DNA derived from dying cells inside the body compartment. The intact DNA is fragmented in these dying cells, and then appears in the bloodstream. These fragments have been shown to cross the kidney barrier and can be detected in urine. Xenomics' technology uses safe and simple urine collection to be applied to a broad range of testing, such as tumor detection, tissue transplants, infectious disease, even bio-terrorism.
The full version of this special report on XNOM can be found at: http://www.allpennystocks.com/apsc/us/article/xnom_may_18_2005.htm
About AllPennyStocks.com:
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and U.S. site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs weekly stocks to watch, has a weekly market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, Nasdaq and OTC BB, and much more information for the average investor.
Although the majority of AllPennyStocks.com reports are independent, it has received compensation for carrying the report on Xenomics Inc. (OTCBB:XNOM), the compensation is twenty thousand dollars by the company. This creates an inherent conflict of interest and readers are encouraged to view the main disclaimer at http://www.allpennystocks.com/apsc/us/disclaimer/index.htm.